Does the pharmacology of oxycodone justify its increasing use as an analgesic?

Trends in Pharmacological Sciences

Volumn 34, Issue 4, 2013, Pages 206-214

  Olkkola, Klaus T ^a   Kontinen, Vesa K ^b   Saari, Teijo I ^c   Kalso, Eija A ^d  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

opioid receptor; morphine; nociception; opiate

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 2D6; GUANINE NUCLEOTIDE BINDING PROTEIN; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; LOPINAVIR; MICONAZOLE; MORPHINE; MU OPIATE RECEPTOR; OXYCODONE; PAROXETINE; QUINIDINE; RIFAMPICIN; RITONAVIR; TELITHROMYCIN; VORICONAZOLE;

ADDICTION; AGE; ANALGESIC ACTIVITY; BINDING AFFINITY; CANCER PAIN; CHRONIC PAIN; CYP2D6 GENE; DRUG DISTRIBUTION; DRUG FATALITY; DRUG INTOXICATION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG USE; FOOD DRUG INTERACTION; GENOTYPE; GRAPEFRUIT JUICE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PAIN; PHARMACOGENOMICS; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; UNSPECIFIED SIDE EFFECT;

ANALGESICS, OPIOID; ANIMALS; HUMANS; OXYCODONE; RECEPTORS, OPIOID, MU;

EID: 84876020205     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.02.001     Document Type: Review

References (81)

1. K. Hamunen Trends in opioid consumption in the Nordic countries 2002-2006 Eur. J. Pain 13 2009 954 962
2. G. Navarro, and H.W. Elliott The effects of morphine, morphinone and thebaine on the EEG and behavior of rabbits and cats Neuropharmacology 10 1971 367 377
3. B. Lalovic Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites Clin. Pharmacol. Ther. 79 2006 461 479
4. E.M. Peckham, and J.R. Traynor Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats J. Pharmacol. Exp. Ther. 316 2006 1195 1201
5. K.K. Lemberg Pharmacology of oxycodone: does it explain why oxycodone has become a bestselling strong opioid? Scand. J. Pain 1 2009 S18 S23
6. C.M. Thompson Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors J. Pharmacol. Exp. Ther. 308 2004 547 554
7. C.K. Nielsen Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the dark agouti rat J. Pharmacol. Exp. Ther. 295 2000 91 99
8. C. Nozaki Antinociceptive effect of oxycodone in diabetic mice Eur. J. Pharmacol. 524 2005 75 79
9. C. Nozaki Characterization of the antinociceptive effects of oxycodone in diabetic mice Eur. J. Pharmacol. 535 2006 145 151
10. C. Nozaki, and J. Kamei Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice Eur. J. Pharmacol. 560 2007 160 162
11. P.M. Beardsley Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys Exp. Clin. Psychopharmacol. 12 2004 163 172
12. M. Pawar Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2 Eur. J. Pharmacol. 563 2007 92 101
13. M. Narita Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine Neuropsychopharmacology 33 2008 1097 1112
14. A. Nakamura Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model Br. J. Pharmacol. 168 2013 375 388
15. C.K. Nielsen Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain Pain 132 2007 289 300
16. E.A. Bolan Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes J. Pharmacol. Exp. Ther. 303 2002 557 562
17. K.K. Lemberg Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia Anesth. Analg. 106 2008 463 470
18. T.F. Meert, and H.A. Vermeirsch A preclinical comparison between different opioids: antinociceptive versus adverse effects Pharmacol. Biochem. Behav. 80 2005 309 326
19. C.D. Cook, and M.D. Nickerson Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund's adjuvant-induced arthritic male and female rats J. Pharmacol. Exp. Ther. 313 2005 449 459
20. K. Lemberg Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat Anesth. Analg. 102 2006 1768 1774
21. F. Simonin Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal EMBO J. 17 1998 886 897
22. J.N. Sengupta Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon Gastroenterology 111 1996 968 980
23. M.B. Burton, and G.F. Gebhart Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation J. Pharmacol. Exp. Ther. 285 1998 707 715
24. D.S. Weinberg Sublingual absorption of selected opioid analgesics Clin. Pharmacol. Ther. 44 1988 335 342
25. A. Takala Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone Acta Anaesthesiol. Scand. 41 1997 309 312
26. A. Liukas Plasma concentrations of oral oxycodone are greatly increased in the elderly Clin. Pharmacol. Ther. 84 2008 462 467
27. A. Liukas Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups Drugs Aging 28 2011 41 50
28. H.H. Villesen Cerebral kinetics of oxycodone in conscious sheep J. Pharm. Sci. 95 2006 1666 1676
29. E.D. Kharasch Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine Clin. Pharmacol. Ther. 74 2003 543 554
30. E.D. Kharasch The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone Br. J. Clin. Pharmacol. 57 2004 600 610
31. E. Boström Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833 J. Pharm. Sci. 94 2005 1060 1066
32. H.E. Hassan Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats J. Pharm. Sci. 96 2007 2494 2506
33. E. Boström Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine Anesthesiology 108 2008 495 505
34. T. Okura Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone Drug Metab. Dispos. 36 2008 2005 2013
35. Y. Nakazawa Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect J. Pharm. Sci. 99 2010 467 474
36. K.A. Moore Tentative identification of novel oxycodone metabolites in human urine J. Anal. Toxicol. 27 2003 346 352
37. K.T. Olkkola Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children Br. J. Clin. Pharmacol. 38 1994 71 76
38. H. Kokki Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children Clin. Pharmacokinet. 43 2004 613 622
39. T.H. Nieminen Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone Anesthesiology 110 2009 1371 1378
40. M-L. Pokela Marked variation in oxycodone pharmacokinetics in infants Paediatr. Anaesth. 15 2005 560 565
41. M. Kokki Intravenous oxycodone for pain relief in the first stage of labour-maternal pharmacokinetics and neonatal exposure Basic Clin. Pharmacol. Toxicol. 111 2012 182 188
42. M. Ingelman-Sundberg, and S.C. Sim Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system Biochem. Biophys. Res. Commun. 396 2010 90 94
43. L.K. Teh, and L. Bertilsson Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance Drug Metab. Pharmacokinet. 27 2012 55 67
44. S.T. Zwisler The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism Basic Clin. Pharmacol. Toxicol. 104 2009 335 344
45. C.F. Samer The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone Br. J. Pharmacol. 160 2010 907 918
46. S.T. Zwisler Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia Acta Anaesthesiol. Scand. 54 2010 232 240
47. T. Naito CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone J. Clin. Pharmacol. 51 2011 1529 1538
48. T.N. Andreassen Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study Eur. J. Clin. Pharmacol. 68 2012 55 64
49. N.M. Hagelberg Voriconazole drastically increases exposure to oral oxycodone Eur. J. Clin. Pharmacol. 65 2009 263 271
50. T.H. Nieminen Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir Eur. J. Clin. Pharmacol. 66 2010 977 985
51. T.H. Nieminen St John's wort greatly reduces the concentrations of oral oxycodone Eur. J. Pain 14 2010 854 859
52. D.R. Mould, and R.N. Upton Basic concepts in population modeling, simulation, and model-based drug development Pharmacomet. Syst. Parmacol. 1 2012 e6
53. M.M.R.F. Struys Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts Br. J. Anaesth. 107 2011 38 47
54. A. El-Tahtawy Population pharmacokinetics of oxycodone in children 6 months to 7 years old J. Clin. Pharmacol. 46 2006 433 442
55. T.I. Saari Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study Br. J. Anaesth. 108 2012 491 498
56. J.W. Mandema Characterization and validation of a pharmacokinetic model for controlled-release oxycodone Br. J. Clin. Pharmacol. 42 1996 747 756
57. C. Staahl Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model J. Clin. Pharmacol. 48 2008 619 631
58. H. Lenz A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy Anesth. Analg. 109 2009 1279 1283
59. R. Pöyhiä, and E.A. Kalso Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats Pharmacol. Toxicol. 70 1992 125 130
60. M.P. Rothwell Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study Br. J. Anaesth. 106 2011 865 872
61. K.K. Lemberg Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats Anesthesiology 105 2006 801 812
62. P. Mucci-LoRusso Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study Eur. J. Pain 2 1998 239 249
63. A. Caraceni Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project Palliat. Med. 25 2011 402 409
64. C. Staahl Multi-modal and tissue-differentiated experimental pain assessment: reproducibility of a new concept for assessment of analgesics Basic Clin. Pharmacol. Toxicol. 98 2006 201 211
65. S. Mercadante Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study Clin. J. Pain. 26 2010 794 797
66. E. Kalso Opioids in chronic non-cancer pain: systematic review of efficacy and safety Pain 112 2004 372 380
67. A.D. Furlan Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects CMAJ 174 2006 1589 1594
68. K. Monory Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans Life Sci. 64 1999 2011 2020
69. B.C. Yoburn Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity Pharmacol. Biochem. Behav. 51 1995 535 539
70. P.A. Lester, and J.R. Traynor Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes Brain Res. 1073 2006 290 296
71. R. Pöyhiä, and T. Seppälä Liposolubility and protein binding of oxycodone in vitro Pharmacol. Toxicol. 74 1994 23 27
72. M. Kirvela The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation J. Clin. Anesth. 8 1996 13 18
73. B. Lalovic Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes Drug Metab. Dispos. 32 2004 447 454
74. K. Fukuda Opioids R.D. Miller, Miller's Anesthesia 7th edn 2010 Churchill Livingstone Elsevier 769 824
75. A. Liukas Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers J. Clin. Psychopharmacol. 31 2011 302 308
76. T.H. Nieminen Grapefruit juice enhances the exposure to oral oxycodone Basic Clin. Pharmacol. Toxicol. 107 2010 782 788
77. T.I. Saari Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone Eur. J. Clin. Pharmacol. 66 2010 387 397
78. J. Grönlund Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone Br. J. Clin. Pharmacol. 70 2010 78 87
79. J. Grönlund Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4 Antimicrob. Agents Chemother. 55 2011 1063 1067
80. T. Heiskanen Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone Clin. Pharmacol. Ther. 64 1998 603 611
81. J. Grönlund Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone J. Clin. Pharmacol. 50 2010 101 108